Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BCDA

BioCardia Inc

Apr 24 • 04:00PM ET

1.16

-0.01 -0.85 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE NTLA CLLS QURE EDIT SGMO FATE BOLD CLRB

| Held by: VXF VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.41	Insider Own	55.03%	Shs Outstand	10.76M	Perf Week	-1.69%
Market Cap	12.69M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	0.15%	Shs Float	4.92M	Perf Month	-3.33%
Enterprise Value	10.72M	PEG	-	EPS next Q	-0.17	Inst Own	6.70%	Short Float	3.59%	Perf Quarter	-13.43%
Income	-8.23M	P/S	-	EPS this Y	48.78%	Inst Trans	4.92%	Short Ratio	2.65	Perf Half Y	-20.55%
Sales	0.00M	P/B	13.94	EPS next Y	19.84%	ROA	-230.57%	Short Interest	0.18M	Perf YTD	-7.20%
Book/sh	0.08	P/C	5.08	EPS next 5Y	31.81%	ROE	-950.12%	52W High	3.20 -63.75%	Perf Year	-36.09%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	50.34% 43.92%	ROIC	-838.74%	52W Low	1.00 16.00%	Perf 3Y	-96.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.92% 5.61%	Perf 5Y	-97.96%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	57.81%	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-99.13%
Dividend Ex-Date	-	Quick Ratio	1.12	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	43.81	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.12	EPS Q/Q	63.03%	SMA20	-2.23%	Beta	0.58	Target Price	15.50
Payout	-	Debt/Eq	0.59	Sales Q/Q	-	SMA50	-3.73%	Rel Volume	0.50	Prev Close	1.17
Employees	17	LT Debt/Eq	0.10	Earnings	Mar 24 AMC	SMA200	-21.47%	Avg Volume	66.71K	Price	1.16
IPO	Nov 13, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	100.00% -	Trades		Volume	33,492	Change	-0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Apr-20-26 08:00AM	BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure (GlobeNewswire) +5.93%
Apr-02-26 10:11AM	BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP System in Ischemic Heart Failure (GlobeNewswire)
Mar-26-26 08:30AM	BioCardia, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-24-26 11:01PM	BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... (GuruFocus.com)
04:05PM	BioCardia Reports 2025 Business Highlights and Financial Results (GlobeNewswire)
07:47PM	Loading…
Mar-19-26 07:47PM	BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 (GlobeNewswire)
Mar-17-26 06:00AM	BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA (GlobeNewswire)
Mar-03-26 08:00AM	BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) (GlobeNewswire) -5.92%
Feb-10-26 09:15AM	BioCardia Files Pre-Submission for FDA Approval of Helix Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart (GlobeNewswire)
Feb-03-26 08:00AM	BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) (GlobeNewswire)
Dec-16-25 08:00AM	BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA (GlobeNewswire)
Dec-03-25 08:00AM	BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno (GlobeNewswire)
Dec-01-25 08:30AM	BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress (GlobeNewswire)
Nov-24-25 08:15AM	BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality (GlobeNewswire)
Nov-12-25 04:40PM	BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
08:30AM	Loading…
Nov-10-25 08:30AM	BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Nov-05-25 07:29PM	BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 (GlobeNewswire)
Oct-30-25 08:00AM	BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Oct-02-25 08:00AM	BioCardia Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-22-25 08:00AM	BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Sep-18-25 09:15AM	BioCardia Announces Pricing of Up To $12 Million Public Offering (GlobeNewswire) -23.78%
07:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up (GlobeNewswire)
Sep-04-25 09:00AM	BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 (GlobeNewswire)
Aug-13-25 08:00AM	BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology (GlobeNewswire) +6.90%
Aug-11-25 09:15AM	BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.15%
Aug-06-25 03:18PM	BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 (GlobeNewswire) -5.52%
Aug-04-25 06:00AM	BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP Cell Therapy for Heart Failure and Helix Transendocardial Delivery Catheter (GlobeNewswire) -7.98%
Jul-24-25 09:00AM	BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP Cell Therapy in Ischemic Heart Failure (GlobeNewswire)
Jul-16-25 08:45AM	Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Jun-25-25 08:00AM	BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
08:30AM	Loading…
May-21-25 08:30AM	BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 (GlobeNewswire)
May-15-25 03:16AM	BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... (GuruFocus.com) -16.25%
May-14-25 04:05PM	BioCardia Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
May-09-25 04:28PM	BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 (GlobeNewswire)
May-06-25 08:00AM	BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
May-02-25 11:03AM	First subject enrolled in BioCardias Phase III heart failure therapy trial (Clinical Trials Arena) -5.96%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and AVANCE Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	Apr 20 '26	Buy	1.23	600	738	275,366	Apr 22 05:04 PM
Altman Peter	President and CEO	Apr 21 '26	Buy	1.23	400	492	275,766	Apr 22 05:04 PM
Altman Peter	President and CEO	Mar 24 '26	Buy	1.24	600	744	274,466	Mar 26 08:05 PM
Altman Peter	President and CEO	Mar 25 '26	Buy	1.22	300	366	274,766	Mar 26 08:05 PM
Altman Peter	President and CEO	Feb 04 '26	Buy	1.13	5,000	5,650	273,866	Feb 04 05:47 PM
Altman Peter	President and CEO	Jan 20 '26	Buy	1.32	600	792	268,566	Jan 21 05:03 PM
Altman Peter	President and CEO	Jan 21 '26	Buy	1.34	300	402	268,866	Jan 21 05:03 PM
Altman Peter	President and CEO	Dec 17 '25	Buy	1.30	900	1,170	267,966	Dec 17 06:32 PM
Altman Peter	President and CEO	Dec 16 '25	Buy	1.37	200	274	267,066	Dec 17 06:32 PM
STERTZER SIMON H	Director	Sep 19 '25	Buy	1.25	398,400	498,000	591,054	Sep 23 09:00 AM
Blank Andrew Scott	Director	Sep 19 '25	Buy	1.25	288,000	360,000	634,023	Sep 23 09:00 AM
Altman Peter	President and CEO	Sep 19 '25	Buy	1.25	48,000	60,000	216,762	Sep 23 09:00 AM
Altman Peter	President and CEO	Aug 22 '25	Buy	1.83	700	1,281	168,762	Aug 25 09:30 AM
Altman Peter	President and CEO	Aug 13 '25	Buy	1.83	100	183	168,062	Aug 13 06:59 PM
Altman Peter	President and CEO	Aug 12 '25	Buy	1.75	400	700	167,962	Aug 12 07:23 PM
Altman Peter	President and CEO	Aug 11 '25	Buy	1.76	1,700	2,989	167,562	Aug 11 07:21 PM
McClung David	Chief Financial Officer	Jun 30 '25	Buy	2.08	4,819	9,999	47,950	Jul 02 09:03 PM
Altman Peter	President and CEO	Jun 30 '25	Buy	2.08	24,096	49,999	165,862	Jul 02 09:02 PM
STERTZER SIMON H	Director	Jun 30 '25	Buy	2.08	72,289	150,000	192,654	Jul 02 09:02 PM
Blank Andrew Scott	Director	Jun 30 '25	Buy	2.08	72,289	150,000	346,023	Jul 02 09:01 PM
Altman Peter	President and CEO	May 30 '25	Buy	2.21	100	221	141,766	May 30 08:55 PM
Altman Peter	President and CEO	May 20 '25	Buy	2.08	1,600	3,328	140,966	May 22 06:45 PM
Altman Peter	President and CEO	May 22 '25	Buy	1.89	700	1,323	141,666	May 22 06:45 PM
Altman Peter	President and CEO	May 16 '25	Buy	2.43	300	730	139,366	May 16 05:31 PM
Altman Peter	President and CEO	May 14 '25	Buy	2.99	100	299	139,066	May 16 05:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCDA

BioCardia Inc

Upgrade your Finviz experience